ReviewFrontiers in urology2025
Integrated management strategies for benign prostatic hyperplasia.
Review in Frontiers in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aquablation/AquaBeam Waterjet Therapy for Benign Prostatic Hyperplasia: Three-Year Functional and Ejaculatory Outcomes in a Multicenter Real-World Italian Cohort.Lower urinary tract symptoms · 2026Article
- The core aquablation pentafecta: a five-domain composite definition of procedural success and learning curve validation in 300 consecutive cases.Journal of robotic surgery · 2026Article
- Pathophysiological mechanisms of benign prostatic obstruction in men with small prostate volume and the emerging role of ultra-minimally invasive prostatic urethral dilation: a narrative review.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is a common condition in aging men, leading to lower urinary tract symptoms (LUTS) that affect quality of life. Treatment options have evolved from invasive surgeries to a combination of pharmacological therapies, minimally invasive surgical therapies (MISTs), and standard surgical procedures. Medications such as α-blockers, 5-alpha reductase inhibitors (5-ARIs), and phosphodiesterase-5 inhibitors (PDE5i) are the first-line treatment for mild-to-moderate BPH, while MISTs like Rezūm, UroLift, Aquablation, and prostatic artery embolization (PAE) provide less invasive alternatives with shorter recovery times. For larger prostates, TURP and HoLEP remain the gold standards, offering effective long-term symptom relief despite some risks. Future advancements in BPH treatment focus on robotic-assisted surgery, AI-guided treatment selection, hybrid therapies, and regenerative medicine, aiming to enhance precision, reduce complications, and improve patient outcomes. This review summarizes current BPH management strategies and explores future innovations in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.